Skip to main content
OpenTrials
Completed

NCT Number: NCT02394431

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

Sickle Cell Disease is a serious disease that is life-threatening for patients being homozygous for the SS form or heterozygous for the SC or βthal forms. The CHU Brugmann hospital currently regularly treats about 70 homozygous adult patients and this number is in constant augmentation.

Sickle cell disease patients may develop a cardiomyopathy due to chronic anemia, the haemosiderosis risk or, less frequently, to coronary vaso-occlusive damages.

The hypervolemia in patients with sickle cell disease causes an overestimation of the ejected left ventricular fraction measured by echocardiography, this parameter being very dependent of the blood volume.It has already been shown that the left ventricular ejection fraction was normal in most patients with sickle cell disease, but that its evaluation by parameters independent from the blood volume showed the existence of a dysfunction.

Myocardial strain, as measured by speckle tracking, is a echographic evaluation method of the cardiac function, independent of the blood volume. This technique hasn't been used much in sickle cell disease patients. A study using 3D speckle tracking on a limited number of sickle cell disease patients failed to show a strain anomaly. Moreover, the study highlighted a higher global longitudinal strain in this patient population. The investigators find these data hard to explain and in contradiction with previous studies using other cardiac function evaluation techniques, independent from the blood volume.

The primary goal of this study is thus

* to study the longitudinal strain by 2D echography * to determine if anomalies of the longitudinal strain exist in sickle cell disease patients with a normal ejected left ventricular fraction, compared to a control group of healthy patients.

The secondary goal of this study is to correlate, inside the sickle cell disease group, the possible strain anomalies with biological gravity parameters of the disease.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All sickle cell disease patients

Exclusion criteria

  • Insufficient echogenicity

Treatment and study plan

Cardiac Echography

Other

Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.

biological parameters

Other

Hemoglobin levels, red cells, hematocrit, iron, ferritin

Clinical parameters

Other

Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness

Primary outcomes

  1. Cardiac ejection fraction

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

    Ejection fraction measured by Teicholz and planimety.

  2. Cardiac diastolic function

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  3. Cardiac tissular doppler

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  4. Myocardiac performance index

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  5. Global longitudinal strain

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

    Global longitudinal strain measured by speckle tracking.

  6. arterial pulmonary hypertension

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  7. left ventricular hypertrophy

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Secondary outcomes

  1. Biological parameters: hemoglobin levels

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  2. Biological parameters: ferritin levels

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  3. Biological parameters: red cells count

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  4. Biological parameters: hematocrit levels

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  5. Biological parameters: iron levels

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

  6. Clinical parameters: severity of the illness

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

    Sickle cell disease organ damages.

  7. Clinical parameters: sanguine transfusion numbers

    Time frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Mar 20, 2015
Registry last updated
Jul 26, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.